Top Suppliers:I want be here



364762-86-7

364762-86-7 structure
364762-86-7 structure
  • Name: TD-198946
  • Chemical Name: 1-Methyl-8-[4-(2-quinolinylmethoxy)phenoxy]-4,5-dihydro-1H-thieno [3,4-g]indazole-6-carboxamide
  • CAS Number: 364762-86-7
  • Molecular Formula: C27H22N4O3S
  • Molecular Weight: 482.55400
  • Catalog: Research Areas Inflammation/Immunology
  • Create Date: 2016-09-09 20:20:12
  • Modify Date: 2024-01-02 01:21:09
  • TD-198946, a thienoindazole derivative, is a potent chondrogenic agent.

Name 1-Methyl-8-[4-(2-quinolinylmethoxy)phenoxy]-4,5-dihydro-1H-thieno [3,4-g]indazole-6-carboxamide
Synonyms 2,3-dihydro-1-methyl-5-(methylthio)-1H-pyrrole
1H-Pyrrole,2,3-dihydro-1-methyl-5-(methylthio)
1-methyl-2-methylthio-2-pyrroline
4,5-dihydro-1-methyl-8-[4-(2-quinolinylmethoxy)phenoxy]-1H-thieno[3,4-g]indazole-6-carboxamide
1-Methyl-2-methylthio-2-pyrrolin
1-methyl-5-(methylsulfanyl)-2,3-dihydro-1H-pyrrole
1-methyl-8-[4-(quinolin-2-ylmethoxy)phenoxy]-4,5-dihydro-1H-thieno[3,4-g]indazole-6-carboxamide
4,5-Dihydro-1-methyl-8-[4-(2-quinolylmethyloxy)phenoxy]-1H-thieno[3,4-g]indazole-6-carboxamide
1-methyl-5-methylsulfanyl-2,3-dihydro-pyrrole
4,5-dihydro-1-methyl-2-(methylthio)-pyrrole
1-methyl-2-methylsulfanyl-4,5-dihydro-1H-pyrrole
TD-198946
Description TD-198946, a thienoindazole derivative, is a potent chondrogenic agent.
Related Catalog
In Vitro TD-198946 is a potent chondrogenic agent. TD-198946 strongly induces chondrogenic differentiation without promoting hypertrophy in cell and metatarsal organ cultures. TD-198946 induces stronger Col2a1 promoter activity than insulin in ATDC5 cells. In C3H10T1/2 cells, ATDC5 cells and primary mouse chondrocytes, TD-198946 dose-dependently stimulates endogenous expression of the chondrocyte markers Col2a1 and Acan, with maximum effects around 1-10 μM[1].
In Vivo When administered directly into the joint space, TD-198946 successfully prevents and repaires degeneration of the articular cartilage. TD-198946 exerts its effect through the regulation of Runx1 expression, which is downregulated in both mouse and human OA cartilage compared with normal tissue[1]. TD-198946 has disease-modifying effects on progressed osteoarthritis. TD-198946 may prevent the progression of osteoarthritis by acting on the remaining chondrocytes rather than repairing damaged cartilage, it may be most effective as a therapeutic during the early or middle stages of osteoarthritis, before the articular cartilage is fully eroded[2]. Cartilaginous cell-sheets are generated by culturing mouse and canine costal chondrocytes and human mesenchymal stem cells with TD-198946 on temperature-responsive dishes. The transplanted cell-sheets are then successfully used to promote the reconstruction of permanent cartilage, with no evidence of chondrocyte hypertrophy in the knee articular cartilage defects created in mice and canines[3].
Animal Admin Mice: Each of the prevention and repair models had two groups: (1) TD-198946-treated animals and (2) saline-treated animals. In all the mice tested the left knee joints underwent the operation and the right knee joints are sham-operated. Mice are re-anaesthetised and given a 10 µL intra-articular injection of TD-198946 or saline immediately after surgery (prevention model) or 4 weeks following surgery (repair model) every 5 days for 8 or 4 weeks, respectively[1].
References

[1]. Yano F, et al. A novel disease-modifying osteoarthritis drug candidate targeting Runx1. Ann Rheum Dis. 2013 May;72(5):748-53.

[2]. Yano F, et al. Disease-modifying effects of TD-198946 on progressed osteoarthritis in a mouse model. Ann Rheum Dis. 2014 Nov;73(11):2062-4.

[3]. Yano F, et al. Cell-sheet technology combined with a thienoindazole derivative small compound TD-198946 for cartilage regeneration. Biomaterials. 2013 Jul;34(22):5581-7.

Molecular Formula C27H22N4O3S
Molecular Weight 482.55400
Exact Mass 482.14100
PSA 120.50000
LogP 5.96590
Appearance light yellow solid
Storage condition -20℃